These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 15247564)

  • 1. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting.
    Oyugi JH; Byakika-Tusiime J; Charlebois ED; Kityo C; Mugerwa R; Mugyenyi P; Bangsberg DR
    J Acquir Immune Defic Syndr; 2004 Aug; 36(5):1100-2. PubMed ID: 15247564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.
    Oyugi JH; Byakika-Tusiime J; Ragland K; Laeyendecker O; Mugerwa R; Kityo C; Mugyenyi P; Quinn TC; Bangsberg DR
    AIDS; 2007 May; 21(8):965-71. PubMed ID: 17457090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
    Idigbe EO; Adewole TA; Eisen G; Kanki P; Odunukwe NN; Onwujekwe DI; Audu RA; Araoyinbo ID; Onyewuche JI; Salu OB; Adedoyin JA; Musa AZ
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):65-9. PubMed ID: 16123684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple self-report measures of antiretroviral adherence correlated in Sierra Leone, but did they agree?
    Kelly JD; Hubenthal EA; Lurton G; Empson SF; Barrie MB; Kargbo B; Wagner GJ; Giordano TP
    Int J STD AIDS; 2013 Dec; 24(12):931-7. PubMed ID: 23970613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
    Laurent C; Kouanfack C; Koulla-Shiro S; Nkoué N; Bourgeois A; Calmy A; Lactuock B; Nzeusseu V; Mougnutou R; Peytavin G; Liégeois F; Nerrienet E; Tardy M; Peeters M; Andrieux-Meyer I; Zekeng L; Kazatchkine M; Mpoudi-Ngolé E; Delaporte E
    Lancet; 2004 Jul 3-9; 364(9428):29-34. PubMed ID: 15234853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
    Kitkungvan D; Apisarnthanarak A; Laowansiri P; Mundy LM
    HIV Med; 2008 Oct; 9(8):636-41. PubMed ID: 18643857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
    Hosseinipour MC; Corbett AH; Kanyama C; Mshali I; Phakati S; Rezk NL; van der Horst C; Kashuba AD
    AIDS; 2007 Jan; 21(1):59-64. PubMed ID: 17148968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome.
    Walsh JC; Mandalia S; Gazzard BG
    AIDS; 2002 Jan; 16(2):269-77. PubMed ID: 11807312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?
    Orrell C; Cohen K; Leisegang R; Bangsberg DR; Wood R; Maartens G
    AIDS Res Ther; 2017 Apr; 14(1):20. PubMed ID: 28376815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens.
    Gifford AL; Bormann JE; Shively MJ; Wright BC; Richman DD; Bozzette SA
    J Acquir Immune Defic Syndr; 2000 Apr; 23(5):386-95. PubMed ID: 10866231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
    Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
    Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-Report Measures in the Assessment of Antiretroviral Medication Adherence: Comparison with Medication Possession Ratio and HIV Viral Load.
    Kabore L; Muntner P; Chamot E; Zinski A; Burkholder G; Mugavero MJ
    J Int Assoc Provid AIDS Care; 2015; 14(2):156-62. PubMed ID: 25421930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
    Bourgeois A; Laurent C; Mougnutou R; Nkoué N; Lactuock B; Ciaffi L; Liégeois F; Andrieux-Meyer I; Zekeng L; Calmy A; Mpoudi-Ngolé E; Delaporte E
    Antivir Ther; 2005; 10(2):335-41. PubMed ID: 15865228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
    AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physician estimate of antiretroviral adherence in India: poor correlation with patient self-report and viral load.
    Walshe L; Saple DG; Mehta SH; Shah B; Bollinger RC; Gupta A
    AIDS Patient Care STDS; 2010 Mar; 24(3):189-95. PubMed ID: 20214487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors before enrolment are associated with being removed from a Pharmacy-only Refill Programme at a large urban HIV/AIDS clinic, Uganda.
    Nakiwogga-Muwanga A; Katabira E; Kiragga A; Kambugu A; Nakibuuka-Lubwama E; Manabe YC; Alamo ST; Colebunders R
    Int J STD AIDS; 2014 Feb; 25(2):105-12. PubMed ID: 23970633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV.
    Grossberg R; Zhang Y; Gross R
    J Clin Epidemiol; 2004 Oct; 57(10):1107-10. PubMed ID: 15528063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.